Cholecystokinin

Summary

Cholecystokinin (CCK) is an endogenous gastrointestinal peptide hormone and neurotransmitter released from I-cells in the duodenum and jejunum in response to dietary fats and proteins. It plays central roles in digestion, satiety, and gut-brain signaling. Synthetic CCK and analogs are used primarily as research and diagnostic tools; no formulation is broadly approved for therapeutic use.

Mechanism of Action

Binds to cholecystokinin receptors (CCK1/CCK-A and CCK2/CCK-B), stimulating gallbladder contraction, pancreatic enzyme and bicarbonate secretion, intestinal motility, and satiety signaling via vagal afferents and hypothalamic pathways.

Routes of Administration

Goals & Uses

• Pancreatic function testingDiagnosticHigh
• Anxiety and panic disorder modulationNeuropsychiatricLow
• Gallbladder visualization (cholecystography)DiagnosticHigh
• Gastroparesis / GI motilityGastrointestinalLow
• Appetite suppression / satietyMetabolicModerate

Contraindications

• PregnancyPopulationModeratePotential fetal risk or insufficient safety data
• Biliary obstructionBiliaryHigh
• Acute pancreatitisGastrointestinalHigh
• Hypersensitivity to CCK or sincalideAllergyHigh

Adverse Effects

• AnaphylaxisImmunologicRareSevere life-threatening allergic reaction
• HypotensionCardiovascularUncommonLow blood pressure
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• Panic attacks (CCK-4 fragment)NeuropsychiatricCommon
• Abdominal cramping / painGastrointestinalCommon
• DiarrheaGastrointestinalUncommonLoose or frequent stools

Drug Interactions

• Calcium channel blockersLow
• Anticholinergic agentsModerate
• Opioid analgesicsModerate

Population Constraints

• Pediatric patientsAgeRelative
• Pregnant womenReproductiveRelative
• Patients with anxiety disordersPsychiatricRelative

Regulatory Status

• European UnionUnknownCeruletide (CCK analog) has had limited use in some European countries; regulatory status varies.
• United StatesApprovedApproved: Cholecystography (gallbladder contraction stimulation), Pancreatic function testing (as sincalide/Kinevac)Sincalide (CCK-8 synthetic analog) approved by FDA as diagnostic agent. Full-length CCK is not approved therapeutically.
• United KingdomUnknownNo current MHRA-approved CCK therapeutic product identified; used mainly in research and diagnostics.

Sincalide (CCK-8 sulfated synthetic octapeptide fragment) is FDA-approved as a diagnostic agent (Kinevac) for cholecystography and pancreatic function testing. Full-length CCK is not an approved therapeutic. Peptide analogs are under investigation for metabolic and psychiatric indications.

Evidence & Sources

No sources recorded yet.